Prevalence of bisphosphonate-related osteonecrosis in patients with cancer could be as high as 13.3 percent.
SYSTEMATIC REVIEW CONCLUSION: The overall mean weighted prevalence of bisphosphonate-related osteonecrosis (BON) in the evaluated studies was 6.1 percent, and the overall weighted prevalence of BON in studies with documented follow-up was 13.3 percent. CRITICAL SUMMARY ASSESSMENT: There is inconsistency in prevalence study results and a lack of studies in which investigators have evaluated quality-of-life issues related to or the economic effects of BON in patients with cancer.
Department of Restorative Dentistry and Biomaterials Sciences, Castle Society, Harvard School of Dental Medicine, 188 Longwood Ave., Boston, MA 02115, USA. romesh_nalliah@hsdm.harvard.edu
Romesh
R
Nalliah